Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Nexgenia
AddedFeb 16, 2024
UpdatedJun 18, 2026
Nexgenia

Nexgenia

Seed

Nexgenia, based in Seattle, creates stimuli-responsive polymers and nanoparticles for enhanced molecular separations and sensitive immunoassays.

HQ
Seattle, WA, US
Founded
2011
Overview
Compare
Fundraising
Employees
Website

Nexgenia, founded in Seattle, focuses on developing and manufacturing proprietary stimuli-responsive polymers and polymer-containing magnetic nanoparticles. These innovative materials change state in response to environmental factors such as temperature, pH, and salt, enabling enhanced molecular separations and sensitive immunoassays. Nexgenia's core mission is to revolutionize the fields of molecular diagnostics and therapeutic research by providing advanced tools that improve efficiency and accuracy.

Notable affiliations include Barrett J. Nehilla, a Senior Scientist at Nexgenia, who has contributed significantly to the field through publications in reputable journals. The company has received a Phase SBIR grant from the National Institute of Allergy and Infectious Disease (NIAID) and collaborates with Seattle Children’s Research Institute to advance immunotherapy research. These achievements underscore Nexgenia's impact on scientific research and its potential to drive innovation in medical diagnostics and treatments.

Nexgenia - Similar Companies

Nvigen logo

Nvigen

nvigen.com

NeXtGen Biologics logo

NeXtGen Biologics

NX Pharmagen logo

NX Pharmagen

nxpharmagen.com

NExTNet logo

NExTNet

nextnetinc.com

Nanite logo

Nanite

nanitebio.com

NexGen Arrays logo

NexGen Arrays

IgGenix logo

IgGenix

iggenix.com

Nanonex logo

Nanonex

nanonex.com

Nextrna Therapeutics logo

Nextrna Therapeutics

Nanogen logo

Nanogen

nanogen.com

GeniPhys logo

GeniPhys

geniphys.com

SenGenix logo

SenGenix

sengenix.com

OmegaGenesis logo

OmegaGenesis

nexTC logo

nexTC

Arrogene logo

Arrogene

Nexgenia - Quick Facts

Who are Nexgenia's competitors?

Companies similar to Nexgenia include Nvigen, NeXtGen Biologics, NX Pharmagen and NExTNet.

When was Nexgenia founded?

Nexgenia was founded in 2011.

Where is Nexgenia's headquarters located?

Nexgenia's headquarters is located in Seattle, WA, US.

When was Nexgenia's last funding round?

Nexgenia's most recent funding round was for $1.9M (USD) in August 2016.

How much has Nexgenia raised to-date?

As of Aug 19, 2016, Nexgenia has raised a total of $3.5M (USD).

How many employees does Nexgenia have?

Nexgenia has 3 employees as of Feb 5, 2024.

Nexgenia - Classification

Industry
  • Hardware
Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
  • Transactional
Customer
  • Enterprise
  • Government
Main Product
  • Nanoparticles
  • Polymers
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified